<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01497041</url>
  </required_header>
  <id_info>
    <org_study_id>KSWOG 2010-3</org_study_id>
    <nct_id>NCT01497041</nct_id>
  </id_info>
  <brief_title>A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment</brief_title>
  <official_title>A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korean South West Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korean South West Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Goals

           The primary goal of this phase II trial is to:

           evaluate the response rate of combination chemotherapy with docetaxel and oxaliplatin in
           patients with stage IIIB/IV non-adenocarcinoma, non-small cell lung cancer (NSCLC) as
           second-line treatment

           Secondary goals are to:

           evaluate the treatment-related toxicities of this combination, investigate
           progression-free survival (PFS) and overall survival (OS) in this population

        2. Design The proposed clinical trial is an open label, non-comparative, multicenter phase
           II trial according to the two stage testing design by Simon two-stage testing procedure
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>2years</time_frame>
    <description>Assessment of response will be assessed according to RECIST v1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2years</time_frame>
    <description>Overall survival will be calculated by Kaplan-Meier method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Progression free survival will be calculated by Kaplan-Meier method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of toxicity will be assessed according to CTCAE version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>2 years</time_frame>
    <description>Quality of life will be assessed according to EORTC QLQ-C30, LC13</description>
  </secondary_outcome>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Carcinoma, Squamous</condition>
  <condition>Carcinoma, Large Cell</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel (diluted in 250 ml of 5% dextrose solution, over 60 minutes) 35 mg/m2 IV (D1, D8) every 3 weeks</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin (diluted in 500 ml of 5% dextrose solution, over 120 minutes) 60 mg/m2 IV D1 every 3 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who were diagnosed as non-adenocarcinoma, non-small cell carcinoma of lung
             histologically or cytologically

          2. Patients must be ≥ 18 years old of age

          3. ECOG performance status ≤ 1

          4. Estimated life expectancy of more than 3 months

          5. Treatment with only one prior chemotherapy

          6. At least one lesion that can be measured by imaging (CT/MRI) according to the Response
             Evaluation Criteria in Solid Tumors (RECIST v1.1)

          7. Adequate bone marrow function (absolute neutrophil count [ANC] ≥ 1,500/µL, hemoglobin
             ≥ 9.0 g/dL [correction by transfusion is acceptable], and platelets ≥ 100,000/µL)

          8. Adequate kidney function (serum creatinine &lt; 1.5 x upper limit of normal [ULN])

          9. Adequate liver function (serum total bilirubin &lt; 1.5xULN; serum transaminases levels &lt;
             2.5xUNL)

         10. Provision of fully informed consent prior to any study specific procedures

        Exclusion Criteria:

          1. Pregnant or breastfeeding women and women of childbearing potential not employing
             adequate contraception

          2. Patients who received prior chemotherapy including paclitaxel or docetaxel

          3. Patients with second primary cancer (except, adequately treated non-melanoma skin
             cancer, curatively treated in-situ cancer of the cervix, or other solid tumors
             curatively treated with no evidence of disease for ≥5 years)

          4. Patients with defect of central nervous system (CNS) or any psychiatric disorders and
             CNS metastases

          5. Other serious illness or medical conditions A. Clinically significant cardiac disease
             (uncontrolled congestive heart disease despite treatment [NYHA class III or IV],
             symptomatic coronary artery disease, unstable angina or myocardial infarction,
             conduction abnormality like grade 2 AV block, serious arrhythmia needed for
             medication, uncontrolled hypertension) within 6 months prior to study entry B. Liver
             cirrhosis (≥ Child-Pugh class B) C. History of significant neurologic or psychiatric
             disorders including dementia or seizures D. Active uncontrolled infection E. Other
             serious underlying medical conditions which could impair the ability of the patient to
             participate in the study

          6. Concomitant administration of any other experimental drug under investigation, or
             concomitant chemotherapy, hormonal therapy, or immunotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Byung Bae, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soonchunhyang University Cheonan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sang Byung Bae</last_name>
    <phone>+82-41-570-3667</phone>
    <email>baesan@schmc.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hwan Jung Yun</last_name>
    <phone>+82-42-280-7157</phone>
    <email>hjyun@cnu.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Soonchunhyang University Cheonan Hospital</name>
      <address>
        <city>Cheonan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Byung Bae, M.D.</last_name>
      <phone>+82-41-570-3667</phone>
      <email>baesan@schmc.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Sang Byung Bae, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Han Jo Kim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kyu Taek Lee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Cheongju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ki Hyeong Lee</last_name>
      <phone>+82-43-269-6015</phone>
      <email>kihlee@chungbuk.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Hye Suk Han</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ki Hyeong Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hwan Jung Yun</last_name>
      <phone>+82-42-280-7157</phone>
      <email>hjyun@cnuh.co.kr</email>
    </contact>
    <investigator>
      <last_name>Hwan Jung Yun</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sam Yong Kim</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyo Jin Lee</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Daejeon ST. Mary's Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suk Young Park</last_name>
      <phone>+82-42-220-9832</phone>
      <email>sypark1011@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Suk Young Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Young Joon Yang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ji Chan Park</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eun-Kee Song</last_name>
      <phone>+82-63-254-1609</phone>
      <email>eksong@jbnu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Eun-Kee Song</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chang-Yeol Yim</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Na-Ri Lee</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2011</study_first_submitted>
  <study_first_submitted_qc>December 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2011</study_first_posted>
  <last_update_submitted>December 19, 2011</last_update_submitted>
  <last_update_submitted_qc>December 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma, Large Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

